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Dr Peter Nelson (Gainesville, Fla). Dr Arthurs and his coau-
thors have scientifically brought to our attention the limitations of
conventional angiography or what can be referred to as a 2D “lume-
nagram.” From their data, intravascular ultrasound (IVUS) provides
significant additional detail with respect to arterial morphology, spe-
cifically the measurement of true vessel outer wall diameter, area
stenosis, and lesion length, all of which are underestimated by angiog-
raphy, and importantly, information regarding plaque morphology
and virtual histology that is simply unavailable from angiography
alone. I offer the following technical and practical questions:
First, in your study angiography was accurate at predicting
luminal diameters and importantly, maximal diameter stenosis.
Isn’t this enough information to make intraprocedural decisions
regarding intervention, or do we need more information? For
example, is the additional information that IVUS provides regard-
ing full vessel diameter really necessary since it is standard practice
to oversize stents and devices based on conventional angiography?
Or, does the area of stenosis really add anything? The case example
that you showed in your presentation I think is certainly telling, but
if there is a false-negative on angiography, do you think that that
lesion would turn out to be hemodynamically significant?
Second, with the increased capability and utility of noninvasive
imaging such as CT [computed tomography] or MR [magnetic
resonance] angiography (CTA or MRA), is some or all of this infor-
mation potentially obtainable before performing angiography and
therefore be potentially useful information for case-based planning?
Third, you point out that you had relatively few heavily
calcified arteries in your study. Was this the result of case selection
and/or do you have experience with calcified vessels and how does
IVUS perform in that setting? Does shadowing or signal drop-out
limit its utility in such cases?
Next, you have excluded chronic total occlusions in order to
maintain the focus of the study, but do you have information as to
whether there is any utility for IVUS in chronic occlusions and, if
so, what information it provides?
And finally, can IVUS provide any hemodynamic information,
either pressure readings or, more importantly, Doppler velocities or
color flow measurements which would really provide added utility in
determining the hemodynamic significance of stenotic lesions and
then, in turn, ultimately guide the adequacy of your intervention.
Dr Zachary M. Arthurs. In regard to the first question,
angiography provides a good luminal assessment. Does knowing
the true vessel diameter and area of stenosis really matter? In order
to understand the extent of atherosclerotic burden, I think the true
vessel and area stenosis are important. In the example illustrated,
the superficial femoral artery appears to be a reasonably healthy
vessel by angiography, but it is truly diseased throughout the entire
length. This accounts for significant underestimation of disease.
Are these lesions hemodynamically significant? Pressure mea-
surements over long lesions are difficult to interpret. At this time,
I would rely on noninvasive physiologic testing in order to deter-
mine their clinical impact. Based on the observation nature of the
current study, I can determine the overall clinical impact of IVUS.
In the current state, surface imaging cannot obtain the reso-
lution needed to assess the vessel wall in the periphery. Magnetic
resonance imaging has been evaluated extensively in the carotid
bed, and computed tomography in the coronary bed. In the
periphery, it is very good for case planning, but I don’t think it
adequately assesses extent of disease.
In regard to the extent of calcification identified in our study,
I think this is appropriate for the population studied. We have
observed increasing calcification as you proceed down the periph-
eral tree, specifically in the tibioperoneal trunk and in the tibial
vessels. Since our cohort was primarily superficial femoral artery
lesions, I think this is an accurate finding. In addition, the angio-
graphic evaluators, although experienced, overestimated calcifica-
tion compared to IVUS.Utilizing IVUS for chronic total occlusions poses several
challenges. Placing the catheter in a subintimal plane vs through a
central core will add variability to the interpretation. If predilation
is needed in order to pass the 3.5F catheter, the images will be
obscured as well. For these reasons, we have not utilized IVUS
consistently for chronic total occlusions.
In my experience, I have not used IVUS to assess hemody-
namic information. At the current time, flow velocities and pres-
sure measurement are not able to be measured.
Dr Hasan Dosluoglu (Buffalo, NY). All the operators in this
groupwere experienced, and although I thought that there was a 10%
mismatch overall, the example you showed us was 74%. So what was
the variation of the scores between the angiographic assessment and
the IVUS assessment? What was the plus and minus standard devia-
tion of that 10%?Which particular lesions were these very experienced
operators particularly wrong? In other words, which type of vessels or
lesions would IVUS be most beneficial to the interventionist?
Dr Arthurs. The example I gave you, of course, was an extreme
example, 20% to 30%, to an area of stenosis of 76%. Even if you did a
luminal calculation on that vessel I showed you, you would still
probably get a 30% or 40% stenosis because it is diffusely diseased
along the entire vessel and you are not using the true vessel diameter
as your denominator to calculate the stenosis. On average, luminal
diameter assessment underestimates the area of stenosis by 10%.
Angiographic evaluates were most discordant when it came to
the qualitative assessment of the plaque. There was actually very good
agreement on the luminal calculations of diameter and stenosis.
Dr Anil Hingorani (Brooklyn, NY). How much did it cost?
Dr Arthurs. Looking at the IVUS catheter itself, depending
on your pricing that you are able to obtain, each individual catheter
could be as low as $700 to as high as $1200, I’ve been told by some
vascular surgeons that use them. On top of that, you have to buy or
lease the actual hard drive, monitors, and software.
DrHingorani.Has this resulted in a change in your practice?
Dr Arthurs. Today, no. It makes me more conscious when
interpreting peripheral angiograms and basing either endoluminal
or surgical therapy.
Dr Hingorani. And finally, can you just go into a little more
detail how 93 patients were selected out of 3200 patients, roughly?
Dr Arthurs. That illustrates the enrollment difficulties. The
main enrollment barrier was identifying patients that had a patent
vessel with an indication to undergo angiogram; and in addition,
patient hesitation to consent for something that they otherwise
would not have obtained if they weren’t part of the study.
Dr Panagiotis Kougias (Houston, Tex). Most people would
agree that one of the best applications of IVUS would be to assess
the adequacy of an endovascular intervention in the SFA.Have you
used this at all for this purpose?
Dr Arthurs. I have used it for that application, but only have
anecdotal experience.
Dr Vikram Kashyap. I just wanted to put this study in
context. This is part of an NIH [National Institutes of Health]-
sponsored study. In this particular report we looked at the disparity
between IVUS results and angiography in lower extremity lesions.
We all know that there is a finite durability of our endovascular
therapies. It may vary from institution, from the area of the
vasculature treated, or from the modality that’s used, but we all
know that the durability is limited.
I think one takeaway message is often we don’t treat resteno-
sis, but what we treat is remnant disease that we didn’t recognize
initially.
The second point is that the virtual histology is a very compel-
ling area. We hope to eventually get parameters that are predictive
of success or failure. That is, highly calcific vessels may be better
treated with one modality, such as atherectomy or cryoplasty, and
perhaps fibrous lesions are better treated with another modality
like stenting. We are not there yet, but that is the goal.
